Radiation Oncology Treatment Options

Cooperman Barnabas offers both state-of-the-art treatment capabilities and the versatility to provide each patient with an individualized, effective treatment plan. In part, our leadership in the field of radiation oncology may be attributed to our technological resources. Combined with the expertise of our medical and support staff, our services and equipment make us one of the most advanced programs in the country.

Our program includes the following:

• Brachytherapy
• CyberKnife®
• Sterotactic Body Radiation Therapy (SBRT)
• Halcyon™
• Image-Guided Radiation Therapy (IGRT)
• Intensity Modulated Radiation Therapy (IMRT)

• Low Dose Radiation Therapy for Osteoarthritis

  For most patients, osteoarthritis is first treated with over-the-counter and prescription medications, physical therapy, and/or joint injections. A joint replacement surgery may be offered when those options no longer provide suitable pain relief. However, low-dose radiation therapy is an option for people who have inoperable osteoarthritis or want to avoid surgery.

  Low-dose radiation therapy is a painless treatment for osteoarthritis that targets the inflammatory cells of the affected joint. It uses a tiny fraction of radiation, as the dose is designed to not destroy tissue. This therapy does not change the joint structure itself, but instead it helps decrease pain signals within the joint and relieve the inflammation that contributes to pain, resulting in less pain and improved joint function.

  While low-dose radiation therapy isn’t a cure, it is a safe, non-surgical option that can help people get their independences back. For the right patients it can make a big difference, helping to calm inflammation and reduce pain. Low-dose radiation therapy does not limit a patient’s ability to have joint replacement surgery in the future if they decide it is right for them.

• Lutathera
• PLUVICTO® is indicated for the treatment of men with an advanced prostate cancer called prostate-specific membrane antigen – positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC). It is an option for someone with PSMA-positive mCRPC that has spread to other parts of the body, and who has already been treated with other anticancer treatments. PLUVICTO® is administered intravenously every six weeks for up to six doses.
• Prone Positioning for Breast Cancer Treatment
• Radium 223 / Xofigo™ for Prostate Cancer
• Selective Internal Radiation Therapy (SIRT)
• Skin Cancer Radiation Treatment
• SpaceOAR®
• Stereotactic Radiosurgery (SRS)
• Truebeam™
• Three linear accelerators: Computer-controlled accelerators provide dynamic and precise treatment delivery. Each linear accelerator utilizes external beams of radiation to offer a comprehensive range of energies and techniques, including a Tomotherapy unit and Elekta Infinity.